Dare Bioscience (DARE) Deferred Taxes (2017 - 2018)
Dare Bioscience's (DARE) quarterly Deferred Taxes came in at $419.0 in Q4 2018, up 78.3% YoY from $235.0 in Q4 2017, and down 95.33% on a QoQ basis from $8975.0 in Q3 2018.
Dare Bioscience (DARE) Deferred Taxes (2017 - 2018) Analysis & Trends
Dare Bioscience (DARE) has 2 years of Deferred Taxes data on file, last reported at $419.0 in Q4 2018.
- Quarterly Deferred Taxes rose 78.3% year-over-year to $419.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $9319.0 (changed N/A YoY) and the FY2018 annual result came in at $9319.0, up 2277.3% from the prior year.
- Deferred Taxes slipped to $419.0 in Q4 2018, from $8975.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $8975.0 in Q3 2018 to a low of -$2571.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Dare Bioscience | 12.49 Mn | -132,469.53 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 419.00 |
| Sep 30, 2018 | 8,975.00 |
| Jun 30, 2018 | -2,571.00 |
| Mar 31, 2018 | 2,496.00 |
| Dec 31, 2017 | 235.00 |
| Sep 30, 2017 | 2,957.00 |